We'll be attending the 4th Cell Therapy Conference in Los Angeles from the 4th-6th. Contact for partnering.

We are attending this years fourth annual Cell Therapy Conference to talk about SistemPSCCheck: bit.ly/2JazRxW

We are hiring! Product Service Support Position (Placement ID: CJCTGUEKKF): bit.ly/2xSArYG R&D Support Position (Placement ID: BHIJNNYAWI): bit.ly/2NO9pN0

Sistemic Announce Global Service and License Agreement for SistemPSCCheck™ bit.ly/2AmKOXl

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products bit.ly/2ThkXHe

The successful development of Sistemic’s SistemPSCCheck™ assay is featured as case studies on both the Innovate UK Analysis for Innovators website and the National Measurement Laboratory for Chemical and Bio-Measurement at LGC website bit.ly/2YjITfW

EPO granted Sistemic the Patent covering the use of microRNAs for quality assessment of stem cell therapy products bit.ly/2HXRyim

Sistemic will be attending Safety of Stem Cell-Derived Therapies bit.ly/2onyW3N

A great two days at ‘Safety of Stem Cell-Derived Therapies: Trends in Future Technologies’ in Edinburgh that Sistemic attended on October 7-8 2019.

Season's Greetings and Happy Holidays! We would just like to take a moment to thank all of our clients, colleagues, collaborators and friends for another rewarding and productive year. We hope you have an enjoyable holiday period and we hope to continue to work with you in 2020.

#CoronaVirusUpdate can be found on our website! We appreciate your patience at this time and please stay safe. sistemic.co.uk/sistemic.co.uk…

As a consequence of the most recent UK and Scottish Governments enforced measures, Sistemic will close at the end of the working day 24th March 2020 until further notice. More details at sistemic.co.uk/sistemic.co.uk…

Sistemic are delighted to announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”. bit.ly/2w2n8YQ

Could #pluripotency ruin your #celltherapy? Read about the current state of the field and how you can avoid residual #ipsc with Sistemic's latest article. Catch the latest news and views on RegMedNet now. bit.ly/2RMN5Hw

We are happy to announce that as of 9.00am (BST) 15/04/20, Sistemic is open again. We have taken steps to allow all staff to work from home, and implemented social distancing measures to allow lab work to be safely carried out in compliance with the UK law.

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs as predictive analytes for cellular function! bit.ly/2ZyjMIT

Season's Greetings and Happy Holidays Despite the extraordinary challenges this year has brought to us all, we would like to take this opportunity to warmly thank you for your business in 2020 and to let you know we look forward to working with you in 2021. Stay safe, Sistemic

Season's Greetings and Happy Holidays Sistemic would like to thank all our clients, colleagues, collaborators and friends for a rewarding and productive year. We hope you have a wonderful holiday period and we hope to continue to work with you in 2023.

Sistemic would like to thank all our clients, colleagues, collaborators and friends for a rewarding and productive year. We hope you have a wonderful holiday period and we hope to continue to work with you in 2025.

Meet us at Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit to discuss our assay for assessment of pluripotent stem cell contamination in derived cell therapy products. bit.ly/2ERGU85